Table 1

Characteristics of patients at baseline and during the follow-up period according to antiplatelet agents

Demographic characteristicClopidogrel (N=384)Aspirin (N=1500)p Value
Men, n (%)229 (59.6%)895 (59.7%)0.991
Age, years, mean±SD70.8±9.571.1±10.20.574
Interval from index stroke to enrolment, day, median (IQR)18 (13–32)16 (11–26)0.113
Comorbidity, n (%)
 Hypertension220 (57.3%)780 (52.0%)0.064
 Diabetes mellitus169 (44.0%)736 (49.1%)0.077
 Ischaemic heart disease64 (16.7%)284 (18.9%)0.307
 Prior stroke/TIA87 (22.7%)280 (18.7%)0.078
 Hyperlipidaemia78 (20.3%)327 (21.8%)0.527
 GI bleeding/peptic ulcer72 (18.8%)39 (2.6%)<0.001
 Charlson index0.8±0.90.8±1.00.774
Medication during the follow-up period
 Statin170 (44.3%)568 (37.9%)0.022
 Other antiplatelet drugs*22 (5.7%)131 (8.7%)0.055
 ACEI/ARB160 (41.7)589 (39.3)0.391
 CCB207 (53.9)822 (54.8)0.754
 Diuretics84 (21.9)261 (17.4)0.043
  • *Dipyridamole, ticlopidine, cilostazole, or aspitin+dipyridamole.

  • ACEI: ACE inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; GI, gastrointestinal; TIA, transient ischaemic attack.